Apologies if this has been asked previously; Is there any possibility of Daybue being prescribed off-label for Fragile X Syndrome (or possibly other conditions being trialled by 2591)?
As FXS is a much higher prevalence than Rett, this could potentially result in significant sales.
Ann: DAYBUE net sales US$66.9 million in Q3 2023, page-13
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.35 |
Change
0.520(3.76%) |
Mkt cap ! $1.834B | |||
| Open | High | Low | Value | Volume |
| $13.96 | $14.35 | $13.66 | $6.469M | 457.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2023 | $14.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.38 | 1777 | 1 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |